Images List Premium Download Classic

Dyslipidemia

Dyslipidemia-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Piperazine derivatives as liver x receptor modulators
Vitae Pharmaceuticals, Inc.
August 10, 2017 - N°20170226067

Provided are novel compounds of formula (i): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are liver x receptor modulators, and which are useful in the treatment of diseases and disorders associated with the liver x receptor. Also provided are the compounds of formula (i) and pharmaceutical compositions thereof for treating atherosclerosis, cardiovascular disease, alzheimer's disease, dermatitis, dyslipidemia, cancer ...
Methods for reducing ldl-cholesterol
Rinat Neuroscience Corp.
August 10, 2017 - N°20170224816

The present invention relates to methods for the treatment of reducing ldl-cholesterol levels in a subject infected with hepatitis c virus (hcv) or at high risk of contracting hcv comprising administration to the subject in need thereof a therapeutically effective amount of an antagonist antibody which specifically binds to a human pcsk9 protein. The subject treatment can be used in ...
[7,6]-fused bicyclic antidiabetic compounds
Merck Sharp & Dohme Corp.
August 03, 2017 - N°20170217942

Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated ...
Dyslipidemia Patent Pack
Download + patent application PDFs
Dyslipidemia Patent Applications
Download + Dyslipidemia-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Dyslipidemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Antidiabetic bicyclic compounds
Merck Sharp & Dohme Corp.
August 03, 2017 - N°20170217918

Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated ...
[5,6]-fused bicyclic antidiabetic compounds
Merck Sharp & Dohme Corp.
July 27, 2017 - N°20170210727

Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated ...
Materials and methods of treating dyslipidemia
Augusta University Research Institute, Inc.
July 20, 2017 - N°20170202907

Described herein are materials and methods for treating dyslipidemia in a mammalian subject in need thereof comprising administering a growth hormone-releasing hormone (ghrh) antagonist or variant thereof to the subject.
Dyslipidemia Patent Pack
Download + patent application PDFs
Dyslipidemia Patent Applications
Download + Dyslipidemia-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Dyslipidemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Bacteroides cect 7771 and the use thereof in the prevention and treatment of excess weight, obesity ...
Consejo Superior De Investigaciones Cientificas
July 06, 2017 - N°20170189456

The invention relates to a strain of bacteroides uniformes with registration number cect 7771, and to the cellular constituents, metabolites and/or secreted molecules thereof. The invention also relates to a composition (nutritional or pharmaceutical) comprising at least one of the previous products. The invention further relates to the use of a strain of bacteroides uniforms, preferably cect 7771, or of the ...
Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in ...
Consejo Superior De Investigaciones Cientificas
June 29, 2017 - N°20170182048

(hereinafter referred to as compound a) for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, in particular hyperlipidemia or mixed dyslipidemia. A further aspect of the present invention relates to a pharmaceutical composition for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, wherein the ...
Treatment of mixed dyslipidemia
Gemphire Therapeutics, Inc.
June 22, 2017 - N°20170172955

Methods and formulations to reduce elevated levels of lipids and apolipoprotein b in subjects having type iib hyperlipidemia. Methods for preventing, delaying or regressing complications of lipid disorders, including; type iib hyperlipidemia, nafld, and nash. Methods for preventing or delaying primary and secondary cardiovascular events. Kits useful for such methods. Methods for reducing hepatic fibrosis. Methods for reducing plasma fibrinogen ...
Antidiabetic substituted heteroaryl compounds
Merck Sharp & Dohme Corp.
June 15, 2017 - N°20170166578

The present invention relates to a compound represented by formula (i): and pharmaceutically acceptable salts thereof. The compounds of formula i are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes ...
Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator
Aveo Pharmaceuticals, Inc.
May 18, 2017 - N°20170137506

The invention provides methods and compositions for treating a subject having a renal-related disorder, such as chronic kidney disease (ckd), end stage renal failure, diabetes, insulin resistance, kidney hypertrophy, kidney hypotrophy, polycystic kidney disease, proteinuria, hyperglycemia, hyperuricemia, gout, kidney stones, hypertension or hypertensive nephropathy, dyslipidemia, anemia and/or reduced erythropoietin production, iron deficiency or hyperfiltration. The methods and compositions use ...
Pharmaceutical compositions of berberine with epa and dha, and methods thereof
Shenzhen Hightide Biopharmaceutical, Ltd.
May 18, 2017 - N°20170135995

The invention provides various novel compositions of berberine in combination with pharmacologically active epa and dha, and related methods of their use in treating various diseases or disorders. The pharmaceutical compositions of the invention are useful in treating and/or preventing various diseases or disorders, including metabolic diseases or disorders such as dyslipidemia, hyperglycemia, hypertriglyceridemia, hyperlipidemia, diabetic dyslipidemia, diabetic hyperlipidemia, ...
Implantable electroacupuncture system and method for treating dyslipidemia and obesity
Valencia Technologies Corporation
May 18, 2017 - N°20170135898

An exemplary method of treating obesity or dyslipidemia of a patient includes 1) generating, by an electroacupuncture device implanted beneath a skin surface of the patient, stimulation sessions at a duty cycle that is less than 0. 05, and 2) applying, by the electroacupuncture device in accordance with the duty cycle, the stimulation sessions to at least one of a saphenous nerve and a ...
Dyslipidemia Patent Pack
Download + patent application PDFs
Dyslipidemia Patent Applications
Download + Dyslipidemia-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Dyslipidemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing ...
Hyundai Pharm Co., Ltd.
April 27, 2017 - N°20170114072

The present invention relates to: a cyclohexene derivative; a preparation method therefor; and a pharmaceutical composition for preventing or treating metabolic diseases, containing the same as an active ingredient. The cyclohexene derivative according to the present invention increases the intracellular activity of cyclic adenosine monophosphate (camp) by activating g protein-coupled receptor 119 (gpr-119) and simultaneously exhibits weight loss and hypoglycemic effects ...
Therapeutic agent for dyslipidemia
Kowa Company, Ltd.
April 27, 2017 - N°20170112811

The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low hdl blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. Which comprises (a) a compound represented by the general formula (1) (in the ...
Novel compounds as diacylglycerol acyltransferase inhibitors
Glaxosmithkline Llc
March 23, 2017 - N°20170081342

This invention relates to novel compounds which are inhibitors of acyl coenzyme a: diacylglycerol acyltransferase 1 (dgat-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to dgat-1 dysfunction or where modulation of ...
Antidiabetic tricyclic compounds
Merck Sharp & Dohme Corp.
March 23, 2017 - N°20170081287

Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated ...
Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses
Esperion Therapeutics, Inc.
March 16, 2017 - N°20170073286

The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, alzheimer's disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination ...
Treatment of metabolic disorders in equine animals
Boehringer Ingelheim Vetmedica Gmbh
March 16, 2017 - N°20170071969

A sglt2 inhibitor or a pharmaceutically acceptable form thereof is provided for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, a sglt2 inhibitor or a pharmaceutically acceptable form thereof is provided for use in the treatment and/or prevention of insulin resistance, hyperinsulinemia, impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic ...
Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
Novartis Ag
March 09, 2017 - N°20170065678

The invention relates to the identification of new therapeutic methods for the fgf21 polypeptide or protein, or mutants, variants, and fusions thereof, for instance, in treating metabolic diseases associated defects in insulin signaling (e. G. Insulin receptor mutation disorders (insr disorders) and/or autoimmune insulin receptor disorders (type b insulin resistance)), defects in insulin production such as type 1 diabetes mellitus, ...
Methods for treating metabolic disorders using fgf
Salk Institute For Biological Studies
March 02, 2017 - N°20170056475

The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.
Loading